Home › Chronic Kidney Disease › Illinois › Cicero
Chronic Kidney Disease clinical trials in Cicero, IL
4 studies for Chronic Kidney Disease are looking for participants at sites in and around Cicero (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
RecruitingPhase 3
- Research Site, Maywood · 5 mi away
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
RecruitingPhase 3
- Research Site, Oak Brook · 9 mi away
Study of BHV-1400 in IgA Nephropathy
RecruitingPhase 1
- Site-009, Hinsdale · 10 mi away
Empagliflozin Treatment in Kidney Transplant Recipients
RecruitingPhase 4
- Edward Hines Jr. VA Hospital, Hines, IL, Hines · 4 mi away
About Chronic Kidney Disease
If your kidneys are damaged and can't filter blood easily, then you may suffer from chronic kidney disease (CKD). Read about the treatments available
More about Chronic Kidney Disease on MedlinePlus
Chronic Kidney Disease trials in other cities
- New York City, NY16 studies
- Boston, MA15 studies
- Philadelphia, PA15 studies
- Dallas, TX15 studies
- Houston, TX15 studies
- Chicago, IL12 studies
- Orlando, FL11 studies
- Atlanta, GA10 studies
- Kansas City, MO9 studies
- Durham, NC9 studies
- San Antonio, TX8 studies
- Washington, DC8 studies
Other studies in Cicero
- Non-Small Cell Lung Cancer24 studies
- Lung Cancer17 studies
- Prostate Cancer14 studies
- Cancer (all types)13 studies
- Acute Myeloid Leukemia11 studies
- Breast Cancer11 studies
- Colorectal Cancer10 studies
- Bladder Cancer8 studies
- Metastatic Cancer7 studies
- Melanoma7 studies
- Cardiovascular Disease7 studies
- Burkitt Lymphoma6 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.